Kyowa Kirin   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Tokyo Japan (1949)

Organization Overview

First Clinical Trial
2002
NCT00456794
First Marketed Drug
1997
toremifene (fareston)
First NDA Approval
1997
toremifene (fareston)
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Kirin Holdings Company, Limited | Kyowa Kirin | KYOWA KIRIN | Kyowa Kirin Korea Co., Ltd. | Kyowa Kirin Pharmaceutical Development, Inc. | Kyowa Kirin Pharmaceutical International Ltd.

Indications

Approved Indications


 

Breast Neoplasms

Parkinson Disease

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 1)

Carcinoma, Non-Small-Cell Lung (Phase 1)

Carcinoma, Transitional Cell (Phase 1)

Dermatitis (Phase 2)

Dermatitis, Atopic (Phase 2)

Eczema (Phase 2)

Familial Hypophosphatemic Rickets (Phase 3)

Gastroparesis (Phase 2)

Hypophosphatemia (Phase 3)

Leukemia (Phase 1)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 1)

Leukemia, Myeloid (Phase 1)

Leukemia, Myeloid, Acute (Phase 1)

Liver Diseases (Phase 1)

Lung Neoplasms (Phase 1)

Movement Disorders (Phase 2)

Myelodysplastic Syndromes (Phase 1)

Parasomnias (Phase 2)

Parkinson Disease (Phase 3)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Preleukemia (Phase 1)

Psychomotor Agitation (Phase 2)

Purpura, Thrombocytopenic, Idiopathic (Phase 2)

Restless Legs Syndrome (Phase 2)

Sleep Wake Disorders (Phase 2)

Syndrome (Phase 2)

Thrombocytopenia (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 20
  • # of Trial APIs: 20